Adaptive Biotechnologies Corp (ADPT) shareholders
Close on Nov 17, 2026Market cap $4.55BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Viking Global Investors LP Joint filing with Halvorsen Ole Andreas (18.80%), Shabet Rose Sharon (18.80%) and 4 more | 29,993,708 | 18.80% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 11,992,448 | 7.90% | 13G (passive) amendment | Dec 31, 2025 |
| Catherine D. Wood Joint filing with ARK Investment Management LLC (5.20%) | 7,732,570 | 5.20% | 13G (passive) | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ADPT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Viking Global Investors LP | 29,993,708 | 18.79% | $643.37M | – | 1.83% |
| BlackRock, Inc. | 15,139,159 | 9.49% | $324.73M | +1,836,134 | 0.00% |
| Vanguard Capital Management LLC | 6,403,587 | 4.01% | $137.36M | +309,443 | 0.00% |
| Wellington Management Group Llp | 5,911,366 | 3.70% | $126.80M | +2,053,944 | 0.02% |
| Vanguard Portfolio Management LLC | 5,476,231 | 3.43% | $117.47M | +984,757 | 0.01% |
| D. E. Shaw & Co., Inc. | 4,625,859 | 2.90% | $99.22M | +2,660,249 | 0.05% |
| Westfield Capital Management Co LP | 4,267,645 | 2.67% | $91.54M | −1,169,073 | 0.30% |
| Geode Capital Management, LLC | 3,641,837 | 2.28% | $78.13M | +5,783 | 0.00% |
| State Street Corp | 3,458,388 | 2.17% | $74.18M | +231,143 | 0.00% |
| Invesco Ltd. | 3,094,011 | 1.94% | $66.37M | −1,356,055 | 0.01% |
| Goldman Sachs Group Inc | 2,984,227 | 1.87% | $64.01M | −257,850 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 2,665,308 | 1.67% | $57.17M | +1,099,095 | 0.01% |
| Driehaus Capital Management LLC | 2,527,703 | 1.58% | $54.22M | +777,102 | 0.31% |
| Arrowstreet Capital, Limited Partnership | 2,524,620 | 1.58% | $54.15M | +529,418 | 0.02% |
| Lord, Abbett & Co. LLC | 2,474,814 | 1.55% | $53.09M | −1,061,289 | 0.15% |
| Nuveen, LLC | 2,366,155 | 1.48% | $50.75M | +1,061,995 | 0.01% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2,182,326 | 1.37% | $46.81M | −505,755 | 0.05% |
| Fred Alger Management, LLC | 2,092,284 | 1.31% | $44.88M | +29,138 | 0.15% |
| ARK Investment Management LLC | 2,090,306 | 1.31% | $44.84M | −2,663 | 0.29% |
| Nomura Asset Management International Inc. | 1,889,188 | 1.18% | $40.52M | +8,005 | 0.06% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 300 | 156M | 97.6% | 49 / 109 | 89 / 42 | 24M | 20M |
| Q1 2026 | 298 | 152M | 95.2% | 57 / 101 | 96 / 38 | 34M | 21M |
| Q4 2025 | 283 | 150M | 94.2% | 52 / 100 | 92 / 38 | 29M | 24M |
| Q3 2025 | 271 | 146M | 91.3% | 55 / 93 | 81 / 25 | 20M | 23M |
| Q2 2025 | 242 | 149M | 93.1% | 46 / 92 | 63 / 26 | 22M | 29M |
| Q1 2025 | 225 | 155M | 97.1% | 40 / 73 | 67 / 19 | 29M | 17M |
| Q4 2024 | 207 | 143M | 89.8% | 46 / 67 | 45 / 23 | 13M | 13M |
| Q3 2024 | 187 | 144M | 90.2% | 32 / 65 | 45 / 20 | 23M | 17M |
| Q2 2024 | 177 | 150M | 93.8% | 25 / 70 | 45 / 37 | 25M | 19M |
| Q1 2024 | 190 | 144M | 90.3% | 28 / 57 | 68 / 37 | 14M | 14M |
| Q4 2023 | 200 | 145M | 90.8% | 38 / 59 | 72 / 26 | 13M | 9M |
| Q3 2023 | 190 | 141M | 88.5% | 16 / 59 | 75 / 34 | 15M | 8M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
275 funds held ADPT in Q2 2026, 42% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ADPT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4,834,309 | 3.03% | $103.70M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,955,565 | 2.48% | $84.85M | 0.10% | Jun 30, 2026 |
| ARK Genomic Revolution ETF | 1,774,756 | 1.11% | $40.06M | 2.57% | Jul 31, 2026 |
| Vanguard Small-Cap Index Fund | 1,742,854 | 1.09% | $37.38M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,684,998 | 1.06% | $38.03M | 0.11% | Jul 31, 2026 |
| Alger Small Cap Focus Fund | 1,494,214 | 0.94% | $33.72M | 3.95% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,422,585 | 0.89% | $30.51M | 0.20% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,415,621 | 0.89% | $30.37M | 0.03% | Jun 30, 2026 |
| Oberweis Micro-Cap Fund | 1,215,600 | 0.76% | $26.07M | 1.61% | Jun 30, 2026 |
| Lord Abbett Developing Growth Fund Inc | 1,194,246 | 0.75% | $26.95M | 1.21% | Jul 31, 2026 |
| Invesco Main Street Small Cap Fund | 1,102,417 | 0.69% | $23.65M | 0.89% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,101,637 | 0.69% | $23.63M | 0.24% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,094,715 | 0.69% | $23.48M | 0.26% | Jun 30, 2026 |
| Nomura Small Cap Growth Fund | 1,084,468 | 0.68% | $23.26M | 1.99% | Jun 30, 2026 |
| SmallCap Fund | 1,031,060 | 0.65% | $23.27M | 1.12% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Chad M. Robins | CEO and Chairman, Director | 2,930,518 | 1.84% | Nov 12, 2026 |
| Julie Rubinstein | President and COO | 377,802 | 0.24% | Nov 13, 2026 |
| Susan Bobulsky | Chief Commercial Officer, MRD | 387,475 | 0.24% | Nov 13, 2026 |
| Francis Lo | Chief People Officer | 223,367 | 0.14% | Oct 5, 2026 |
| Harlan S. Robins | Chief Scientific Officer | 2,104,458 | 1.32% | Jul 23, 2026 |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 299,532 | 0.19% | Jun 30, 2026 |
| Kyle Piskel | Chief Financial Officer | 256,725 | 0.16% | May 20, 2026 |
| Katey Einterz Owen | Director | 66,100 | 0.04% | Sep 2, 2026 |
| Robert Hershberg | Director | 77,347 | 0.05% | Aug 20, 2026 |
| Peter M. Neupert | Director | 255,315 | 0.16% | Aug 19, 2026 |
| Michelle Renee Griffin | Director | 15,625 | 0.01% | Jun 29, 2026 |
| Michael J. Pellini | Director | 69,690 | 0.04% | Mar 6, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Julie Rubinstein President and COO | Nov 13, 2026 | Sale(10b5-1 plan) | −11,466 | $28.93 | $331.71K | 377,802 |
| Julie Rubinstein President and COO | Nov 13, 2026 | Option exercise | +11,466 | $12.14 | $139.20K | 389,268 |
| Julie Rubinstein President and COO | Nov 12, 2026 | Sale(10b5-1 plan) | −11,881 | $29.40 | $349.30K | 377,802 |
| Julie Rubinstein President and COO | Nov 12, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Nov 11, 2026 | Sale(10b5-1 plan) | −6,898 | $31.22 | $215.36K | 377,802 |
| Julie Rubinstein President and COO | Nov 11, 2026 | Sale(10b5-1 plan) | −4,983 | $30.29 | $150.94K | 384,700 |
| Julie Rubinstein President and COO | Nov 11, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Susan Bobulsky Chief Commercial Officer, MRD | Nov 11, 2026 | Sale(10b5-1 plan) | −1,875 | $32.00 | $60.00K | 387,475 |
| Julie Rubinstein President and COO | Nov 10, 2026 | Sale(10b5-1 plan) | −1,900 | $30.41 | $57.78K | 377,802 |
| Julie Rubinstein President and COO | Nov 10, 2026 | Sale(10b5-1 plan) | −9,981 | $29.35 | $292.94K | 379,702 |
| Julie Rubinstein President and COO | Nov 10, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Chad M. Robins CEO and Chairman, Director | Nov 9, 2026 | Gift | −100,000 | – | – | 2,080,518 |
| Julie Rubinstein President and COO | Nov 9, 2026 | Sale(10b5-1 plan) | −2,400 | $30.58 | $73.39K | 377,802 |
| Julie Rubinstein President and COO | Nov 9, 2026 | Sale(10b5-1 plan) | −8,381 | $30.15 | $252.69K | 380,202 |
| Julie Rubinstein President and COO | Nov 9, 2026 | Sale(10b5-1 plan) | −1,100 | $28.87 | $31.76K | 388,583 |
| Julie Rubinstein President and COO | Nov 9, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Nov 6, 2026 | Sale(10b5-1 plan) | −3,481 | $27.88 | $97.05K | 377,802 |
| Julie Rubinstein President and COO | Nov 6, 2026 | Sale(10b5-1 plan) | −8,400 | $27.32 | $229.49K | 381,283 |
| Julie Rubinstein President and COO | Nov 6, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Nov 5, 2026 | Sale(10b5-1 plan) | −500 | $27.70 | $13.85K | 377,802 |
| Julie Rubinstein President and COO | Nov 5, 2026 | Sale(10b5-1 plan) | −5,455 | $26.88 | $146.63K | 378,302 |
| Julie Rubinstein President and COO | Nov 5, 2026 | Sale(10b5-1 plan) | −5,926 | $26.10 | $154.67K | 383,757 |
| Julie Rubinstein President and COO | Nov 5, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Nov 4, 2026 | Sale(10b5-1 plan) | −7,881 | $26.60 | $209.63K | 377,802 |
| Julie Rubinstein President and COO | Nov 4, 2026 | Sale(10b5-1 plan) | −4,000 | $25.78 | $103.12K | 385,683 |
| Julie Rubinstein President and COO | Nov 4, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Nov 3, 2026 | Sale(10b5-1 plan) | −11,881 | $25.98 | $308.67K | 377,802 |
| Julie Rubinstein President and COO | Nov 3, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Nov 2, 2026 | Sale(10b5-1 plan) | −2,585 | $26.34 | $68.09K | 377,802 |
| Julie Rubinstein President and COO | Nov 2, 2026 | Sale(10b5-1 plan) | −9,296 | $25.23 | $234.54K | 380,387 |
| Julie Rubinstein President and COO | Nov 2, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Oct 30, 2026 | Sale(10b5-1 plan) | −2,395 | $27.45 | $65.74K | 377,802 |
| Julie Rubinstein President and COO | Oct 30, 2026 | Sale(10b5-1 plan) | −9,486 | $26.55 | $251.85K | 380,197 |
| Julie Rubinstein President and COO | Oct 30, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Oct 29, 2026 | Sale(10b5-1 plan) | −11,881 | $28.27 | $335.88K | 377,802 |
| Julie Rubinstein President and COO | Oct 29, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Oct 28, 2026 | Sale(10b5-1 plan) | −200 | $28.90 | $5.78K | 377,802 |
| Julie Rubinstein President and COO | Oct 28, 2026 | Sale(10b5-1 plan) | −11,681 | $28.44 | $332.21K | 378,002 |
| Julie Rubinstein President and COO | Oct 28, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Oct 27, 2026 | Sale(10b5-1 plan) | −8,881 | $27.53 | $244.49K | 377,802 |
| Julie Rubinstein President and COO | Oct 27, 2026 | Sale(10b5-1 plan) | −3,000 | $26.58 | $79.74K | 386,683 |
| Julie Rubinstein President and COO | Oct 27, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Oct 26, 2026 | Sale(10b5-1 plan) | −3,378 | $26.30 | $88.84K | 377,802 |
| Julie Rubinstein President and COO | Oct 26, 2026 | Sale(10b5-1 plan) | −8,503 | $25.94 | $220.57K | 381,180 |
| Julie Rubinstein President and COO | Oct 26, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Oct 23, 2026 | Sale(10b5-1 plan) | −7,381 | $25.28 | $186.59K | 377,802 |
| Julie Rubinstein President and COO | Oct 23, 2026 | Sale(10b5-1 plan) | −4,500 | $24.50 | $110.25K | 385,183 |
| Julie Rubinstein President and COO | Oct 23, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Oct 22, 2026 | Sale(10b5-1 plan) | −1,700 | $25.29 | $42.99K | 377,802 |
| Julie Rubinstein President and COO | Oct 22, 2026 | Sale(10b5-1 plan) | −10,181 | $24.38 | $248.21K | 379,502 |
| Julie Rubinstein President and COO | Oct 22, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Oct 21, 2026 | Sale(10b5-1 plan) | −5,882 | $25.57 | $150.40K | 377,802 |
| Julie Rubinstein President and COO | Oct 21, 2026 | Sale(10b5-1 plan) | −5,999 | $25.25 | $151.47K | 383,684 |
| Julie Rubinstein President and COO | Oct 21, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Oct 20, 2026 | Sale(10b5-1 plan) | −100 | $24.85 | $2.49K | 377,802 |
| Julie Rubinstein President and COO | Oct 20, 2026 | Sale(10b5-1 plan) | −11,781 | $24.53 | $288.99K | 377,902 |
| Julie Rubinstein President and COO | Oct 20, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Oct 19, 2026 | Sale(10b5-1 plan) | −11,881 | $24.05 | $285.74K | 377,802 |
| Julie Rubinstein President and COO | Oct 19, 2026 | Option exercise | +11,881 | $12.14 | $144.24K | 389,683 |
| Julie Rubinstein President and COO | Oct 16, 2026 | Sale(10b5-1 plan) | −300 | $25.45 | $7.64K | 377,802 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Adaptive Biotechnologies's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,479 shares on Sep 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Susan Bobulsky Officer | Oct 6, 2026 | 6,444 | $192.29K | Oct 6, 2026 | Restricted Stock Units |
| Julie Rubinstein Officer | Oct 1, 2026 | 379,777 | $10.98M | Oct 1, 2026 | Exercise of Stock Options |
| Francis Lo Officer | Sep 16, 2026 | 142,198 | $3.79M | Sep 16, 2026 | Exercise of Stock Options |
| Susan Bobulsky Officer | Sep 15, 2026 | 1,195 | $29.61K | Sep 15, 2026 | Restricted Stock Units |
| Katherine E Owen Director | Aug 26, 2026 | 9,615 | $249.99K | Aug 26, 2026 | Restricted Stock |
| Harlan S. Robins Former Officer | Aug 20, 2026 | 402,160 | $10.23M | Aug 20, 2026 | Acquired as compensation -- Stock Options |
| Harlan S. Robins Former Officer | Aug 19, 2026 | 215,632 | $5.50M | Aug 19, 2026 | Acquired as compensation -- Stock Options |
| Robert Hershberg Director | Aug 18, 2026 | 30,664 | $748.30K | Aug 18, 2026 | Stock Option Exercise |
| Chad M. Robins Officer | Aug 18, 2026 | 278,676 | $6.84M | Aug 18, 2026 | Acquired as compensation -- Stock Options |
| Harlan S. Robins Former Officer | Aug 18, 2026 | 261,044 | $6.41M | Aug 18, 2026 | Acquired as compensation -- Stock Options |
| Peter M. Neupert Director | Aug 17, 2026 | 124,690 | $3.14M | Aug 17, 2026 | Stock Option Exercise |
| Chad M. Robins Officer | Aug 17, 2026 | 321,324 | $7.96M | Aug 17, 2026 | Acquired as compensation -- Stock Options |
| Harlan S. Robins Former Officer | Aug 17, 2026 | 300,992 | $7.46M | Aug 17, 2026 | Acquired as compensation -- Performance Awards |
| Susan Bobulsky Officer | Aug 10, 2026 | 3,000 | $74.79K | Aug 10, 2026 | Restricted Stock Units |
| Susan Bobulsky Officer | Jul 30, 2026 | 1,299 | $29.31K | Jul 30, 2026 | Restricted Stock Units |
See a number that looks wrong?